Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseases
Aim. An outline of the current potential of pantoprazole in treatment and prevention of upper gastrointestinal diseases.Key points. Pantoprazole is widely applied in gastroesophageal reflux, peptic ulcer disease, Zollinger—Ellison syndrome and for Helicobacter pylori eradication. It minimally inhibi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2021-04-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/538 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860124920315904 |
|---|---|
| author | A. A. Sheptulin S. S. Kardasheva A. A. Kurbatova |
| author_facet | A. A. Sheptulin S. S. Kardasheva A. A. Kurbatova |
| author_sort | A. A. Sheptulin |
| collection | DOAJ |
| description | Aim. An outline of the current potential of pantoprazole in treatment and prevention of upper gastrointestinal diseases.Key points. Pantoprazole is widely applied in gastroesophageal reflux, peptic ulcer disease, Zollinger—Ellison syndrome and for Helicobacter pylori eradication. It minimally inhibits the CYP2C19 isoenzyme involved in the metabolism of many drugs. Pharmacokinetics of pantoprazole conditions a weaker drug interaction compared to other proton pump inhibitors (PPIs), which enables its use for gastrointestinal bleeding prevention in patients receiving dual antiplatelet therapy. The new coronaviral pandemic of COVID-19 urges the selection of PPIs that minimise the drug interference, such as pantoprazole, in therapy and prevention of acid-related upper gastrointestinal diseases. Pantoprazole has a good tolerance and low side effect rate.Conclusion. Pantoprazole is considered among optimal PPIs for efficacy, safety and adherence on the basis of clinical trials for treatment and prevention of gastrointestinal diseases, systematic reviews and meta-analyses. |
| format | Article |
| id | doaj-art-4774a8307f1d44209e86dbd6d26c13b8 |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2021-04-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-4774a8307f1d44209e86dbd6d26c13b82025-02-10T16:14:36ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732021-04-01311475310.22416/1382-4376-2021-31-1-47-53413Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal DiseasesA. A. Sheptulin0S. S. Kardasheva1A. A. Kurbatova2Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Aim. An outline of the current potential of pantoprazole in treatment and prevention of upper gastrointestinal diseases.Key points. Pantoprazole is widely applied in gastroesophageal reflux, peptic ulcer disease, Zollinger—Ellison syndrome and for Helicobacter pylori eradication. It minimally inhibits the CYP2C19 isoenzyme involved in the metabolism of many drugs. Pharmacokinetics of pantoprazole conditions a weaker drug interaction compared to other proton pump inhibitors (PPIs), which enables its use for gastrointestinal bleeding prevention in patients receiving dual antiplatelet therapy. The new coronaviral pandemic of COVID-19 urges the selection of PPIs that minimise the drug interference, such as pantoprazole, in therapy and prevention of acid-related upper gastrointestinal diseases. Pantoprazole has a good tolerance and low side effect rate.Conclusion. Pantoprazole is considered among optimal PPIs for efficacy, safety and adherence on the basis of clinical trials for treatment and prevention of gastrointestinal diseases, systematic reviews and meta-analyses.https://www.gastro-j.ru/jour/article/view/538pantoprazolepeptic ulcergastroesophageal refluxgastrointestinal bleeding conflict of interest: the publication was supported by the krka company |
| spellingShingle | A. A. Sheptulin S. S. Kardasheva A. A. Kurbatova Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseases Российский журнал гастроэнтерологии, гепатологии, колопроктологии pantoprazole peptic ulcer gastroesophageal reflux gastrointestinal bleeding conflict of interest: the publication was supported by the krka company |
| title | Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseases |
| title_full | Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseases |
| title_fullStr | Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseases |
| title_full_unstemmed | Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseases |
| title_short | Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseases |
| title_sort | current potential of pantoprazole in treatment and prevention of gastrointestinal diseases |
| topic | pantoprazole peptic ulcer gastroesophageal reflux gastrointestinal bleeding conflict of interest: the publication was supported by the krka company |
| url | https://www.gastro-j.ru/jour/article/view/538 |
| work_keys_str_mv | AT aasheptulin currentpotentialofpantoprazoleintreatmentandpreventionofgastrointestinaldiseases AT sskardasheva currentpotentialofpantoprazoleintreatmentandpreventionofgastrointestinaldiseases AT aakurbatova currentpotentialofpantoprazoleintreatmentandpreventionofgastrointestinaldiseases |